Combination Therapy Comprising Paclitaxel and 5-Fluorouracil by Using Folic Acid Functionalized Bovine Milk Exosomes Improves the Therapeutic Efficacy against Breast Cancer

Paclitaxel (PAC) has been approved by FDA for clinical use (Taxol(®)), yet dose-dependent severe toxicity due to the adjuvant Cremophor EL(®) in combination with ethanol is a major drawback. The drawbacks of the current therapy can be overcome by (i) finding a suitable vehicle that cannot only bypas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Dulla Naveen, Chaudhuri, Aiswarya, Dehari, Deepa, Shekher, Anusmita, Gupta, Subash C., Majumdar, Shreyasi, Krishnamurthy, Sairam, Singh, Sanjay, Kumar, Dinesh, Agrawal, Ashish Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410314/
https://www.ncbi.nlm.nih.gov/pubmed/36013322
http://dx.doi.org/10.3390/life12081143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410314/
https://www.ncbi.nlm.nih.gov/pubmed/36013322
http://dx.doi.org/10.3390/life12081143

Ejemplares similares